Dr. Moskowitz on Antibody-Drug Conjugates in Relapsed/Refractory DLBCL
November 28th 2022Craig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.
Read More
Dr. Moskowitz on PET-Adapted Therapy in Advanced Hodgkin Lymphoma
April 12th 2019Craig Moskowitz, MD, physician-in-chief, Oncology Service Line, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of PET-adapted therapy in the treatment of patients with advanced-stage Hodgkin lymphoma.
Read More